ITM is a leading radiopharmaceutical biotech company, dedicated to providing a new generation of radiopharmaceutical therapeutics and diagnostics for hard-to-treat tumors. ITM advances a broad precision oncology pipeline, including multiple phase 3 studies, combining the company’s high-quality radioisotopes with a range of targeting molecules.
By leveraging two decades of pioneering radiopharma expertise, central industry position and established global network, ITM strives to provide patients with more effective targeted treatment to improve clinical outcome and quality of life.
